What is William Blair’s Estimate for Hologic Q2 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at William Blair raised their Q2 2025 EPS estimates for shares of Hologic in a research note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will earn $1.07 per share for the quarter, up from their prior forecast of $1.05. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.89 earnings per share.

HOLX has been the subject of several other reports. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. Finally, Evercore ISI boosted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Down 2.1 %

NASDAQ:HOLX opened at $77.54 on Thursday. Hologic has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $18.01 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 2.52 and a beta of 0.98. The business’s fifty day moving average price is $80.77 and its 200 day moving average price is $78.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HOLX. Empowered Funds LLC acquired a new stake in shares of Hologic in the 1st quarter valued at approximately $234,000. Bleakley Financial Group LLC increased its holdings in shares of Hologic by 18.3% during the first quarter. Bleakley Financial Group LLC now owns 5,412 shares of the medical equipment provider’s stock valued at $422,000 after acquiring an additional 836 shares in the last quarter. William Blair Investment Management LLC bought a new position in shares of Hologic in the first quarter valued at $212,000. State Board of Administration of Florida Retirement System raised its stake in shares of Hologic by 2.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 291,729 shares of the medical equipment provider’s stock worth $23,543,000 after purchasing an additional 6,198 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Hologic by 15.3% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,181 shares of the medical equipment provider’s stock valued at $21,687,000 after acquiring an additional 36,898 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.